

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 **Serological markers and Post COVID-19 Condition (PCC) –** 2 **A rapid review of the evidence**

3
4
5 Erin Collins¹, Elizabeth Philippe¹, Chris Gravel^{1,2,3}, Steven Hawken^{1,4}, Marc-André Langlois^{5,6,7},
6 and Julian Little^{1,4,6,8}

7
8 ¹School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario,
9 Canada.

10 ²Department of Mathematics and Statistics, University of Ottawa.

11 ³Department of Epidemiology, Biostatistics and Occupational Health, McGill University

12 ⁴Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

13 ⁵Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario
14 Canada.

15 ⁶Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of
16 Ottawa, Ottawa, Ontario, Canada.

17 ⁷Centre for Infection, Immunity and Inflammation (CI3), University of Ottawa, Ottawa, Ontario, Canada.

18 ⁸The Knowledge Synthesis and Application Unit (KSAU), University of Ottawa, Ottawa, Ontario, Canada.

19

20

21 **Abstract:** 245

22 **Word Count:** 3912

23

24 **Correspondence:** Erin Collins, School of Epidemiology and Public Health, Faculty of Medicine,
25 University of Ottawa. Ottawa, Ontario, Canada. 451 Smyth Road, K1H 8M5. Email:

26 ecoll098@uottawa.ca. Julian Little, School of Epidemiology and Public Health, Faculty of

27 Medicine, University of Ottawa. Ottawa, Ontario, Canada. 451 Smyth Road, K1H 8M5. Email:

28 jlittle@uottawa.ca.

29

30

31

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 **Abstract**

2 **Background:** Post COVID-19 Condition (PCC) is highly heterogeneous, often debilitating, and
3 may last for years after infection. The etiology of PCC remains uncertain. Examination of
4 potential serological markers of PCC, accounting for clinical covariates, may yield emergent
5 pathophysiological insights.

6 **Methods:** In adherence to PRISMA guidelines, we carried out a rapid review of the literature.
7 We searched Medline and Embase for primary observational studies that compared IgG response
8 in individuals who experienced COVID-19 symptoms persisting ≥ 12 weeks post-infection with
9 those who did not. We examined relationships between serological markers and PCC status and
10 investigated sources of inter-study variability, such as severity of acute illness, PCC symptoms
11 assessed, and target antigen(s).

12 **Results:** Of 8,018 unique records, we identified 29 as being eligible for inclusion in synthesis.
13 Definitions of PCC varied. In studies that reported anti-nucleocapsid (N) IgG (n=10 studies;
14 n=989 participants in aggregate), full or partial anti-Spike IgG (i.e., the whole trimer, S1 or S2
15 subgroups, or receptor binding domain, n=19 studies; n=2606 participants), or neutralizing
16 response (n=7 studies; n=1123 participants), we did not find strong evidence to support any
17 difference in serological markers between groups with and without persisting symptoms.
18 However, most studies did not account for severity or level of care required during acute illness,
19 and other potential confounders.

20 **Conclusions:** Pooling of studies would enable more robust exploration of clinical and
21 serological predictors among diverse populations. However, substantial inter-study variations
22 hamper comparability. Standardized reporting practices would improve the quality, consistency,
23 and comprehension of study findings.

24

25

26

27

28

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 **Introduction**

2 Post COVID-19 Condition (PCC) broadly refers to the persistence of symptoms occurring three
3 months or longer post-infection [1-3]. PCC is highly heterogeneous and may manifest as
4 different clusters of symptoms of varying severity and duration [3-7]. While the prevalence of
5 PCC has been found to decrease with increasing months post-infection [8,9], the condition may
6 persist over two years [9,10]. PCC can often have debilitating and wide-ranging impacts, such as
7 diminished quality of life, inability to work or attend school, need for healthcare services,
8 reduced work productivity, and reliance on caregiver support [3,4,10-13]. The etiology of PCC
9 remains uncertain, though several underlying pathophysiological mechanisms, such as cellular
10 damage, inflammatory cytokines, and a hypercoagulable state, are thought to contribute to PCC
11 inception and trajectory [7, 14-17].

12 Given the complexity of the condition, a diverse range of potential predictors warrant
13 consideration. Older age, female sex, pre-existing conditions (e.g., high BMI, asthma, and
14 diabetes), and severity of acute illness, have frequently been proposed as risk factors for post-
15 acute sequelae [3,4,15,18-20]. Additionally, a number of biomarkers have been investigated but
16 currently, there is no consensus as to whether any characterize PCC [14,16,17].

17 Investigation of potential serological markers of PCC, accounting for clinical covariates, may
18 yield pathophysiological insights. To date, several observational studies have compared humoral
19 response between groups with and without persistent symptoms, albeit with highly mixed
20 findings. Most of the evidence to date is on adult populations. Given the utility of serological
21 testing to identify past infection, these efforts may illuminate potential differences in antibody
22 detection that are associated with the presence of persisting symptoms, or specific PCC
23 phenotypes [5,12,17,21-30]. Some studies have found that people with PCC are more likely to
24 elicit a robust humoral response, as compared to people with past COVID-19 infection and no
25 PCC, which could result from viral antigen persistence or over-activation of the immune system
26 [24-27]. On the other hand, findings that people with PCC are more prone to non-response, weak
27 response, or early waning of antibodies may indicate impaired functional antiviral response [21,
28 23, 28-30]. However, investigation of associations between PCC and serological markers are
29 complicated by differences in inclusion criteria, study procedures, serological assays, choice of
30 antibody and target antigen, timing of follow-up for PCC assessment and serological sampling,

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 methods of statistical analysis, and completeness of reporting [3,12,31]. COVID-19 variant and
2 vaccination status may also influence findings [32-36].

3 We performed a systematic search of the literature to collect and collate serological comparisons
4 between adults with and without persistent symptoms following COVID-19 infection. The aims
5 of this review were to 1) assess relationships between post-infection serological response and
6 PCC, and 2) investigate and report on sources of inter-study heterogeneity.

7 **Methods**

8 We completed a rapid review [37] of the literature to examine serological results compared
9 between groups with and without persistent symptoms post COVID-19 infection. We reported
10 findings in accordance with the Preferred Reporting Items for Systematic Review and Meta-
11 Analysis (PRISMA) Statement [38] (**Supplementary Materials**), and registered our review in
12 PROSPERO (CRD42023402978). A protocol was not prepared.

13 **Search strategy and study eligibility**

14 We searched Medline and Embase for reports published between January 1, 2020 – October 22,
15 2022. We imposed no language restrictions on the search. We used a search strategy with key
16 terms relating to 1) Post COVID-19 Condition, and 2) observational studies (**Supplementary**
17 **Materials**).

18 We included records which met the following criteria:

- 19 • Primary observational study;
- 20 • Language: English, French, or Italian;
- 21 • ≥ 50 participants and $\geq 75\%$ adults (≥ 16 years of age) assessed for persistent symptoms
22 ≥ 12 weeks post COVID-19 onset/diagnosis;
- 23 • ≥ 1 post-acute (≥ 4 weeks post COVID-19) serology result reported for a) individuals with
24 any persistent symptoms or a persistent symptom(s) of interest (e.g., post-acute fatigue),
25 and compared with results from individuals without any persistent symptoms or a
26 persistent symptom(s) of interest; or b) individuals with varying PCC severity.

27 Preprints were included so long as other eligibility criteria were met.

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 **Study selection and data extraction**

2 Records identified using the search strategy were entered into Covidence Systematic Review
3 Software. All abstracts and full texts were screened for potential inclusion by one author (EC)
4 using pre-piloted criteria generated by consensus. A second author (EP) verified 10% of records,
5 until a kappa/interrater agreement > 0.8 was achieved. An extraction file was created by
6 consensus and piloted in Excel 2016. Two reviewers (EC and EP) extracted data and 10% of
7 extractions were verified until kappa > 0.8 . In the event of a disagreement that could not be
8 resolved by consensus, a third reviewer was available to address (JL).

9 We extracted study characteristics, PCC description and duration, and serological results. We
10 also extracted variables that may have influenced serological results and/or PCC character and
11 trajectory, such as timing of COVID-19 infection, COVID-19 variants and vaccination status,
12 and potential individual-level confounders we identified a priori (age, sex, level of care (LOC)
13 during acute illness; severity of acute illness; number of acute symptoms; and pre-existing
14 conditions, including diabetes, chronic respiratory illness, cardiac disease, and conditions or
15 medications which may suppress immune function). If COVID-19 variant was not specified, we
16 identified that which prevailed in the host country when participants were infected or recruited
17 [39]. If vaccination status was not recorded, we assumed the study population to be non-
18 vaccinated at time of infection if dates of infection or recruitment preceded mass vaccination
19 efforts in the host country [40]. With relation to LOC, we identified study populations as
20 hospitalized, non-hospitalized, or having “mixed” LOC requirements during acute illness. A
21 population was defined as “mixed” if the proportions of hospitalized and non-hospitalized study
22 participants both exceeded 5%.

23 **Evaluation of risk of bias**

24 We used the Newcastle-Ottawa quality assessment scale (NOS) for observational studies to
25 evaluate quality and risk of bias, and an adapted scale for cross sectional studies [41]. The NOS
26 scale assigns points based on selection, comparability, and outcome of interest. A maximum of
27 nine points was assigned to cohort and case control studies and cross-sectional studies were
28 scored up to seven points. Two authors (EC and EP) independently assessed risk of bias, and
29 10% of studies were cross-checked by a second author. In the event of a disagreement that could

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 not be resolved by consensus, a third reviewer was available to resolve any disagreements that
2 could not be resolved by consensus (JL).

3 **Data synthesis**

4 We compared measures of effect (difference, average, prevalence, or risk) of serological
5 response corresponding to PCC status. Given high inter-study variability, we determined that a
6 meta-analysis of results was not appropriate and instead presented a narrative description of
7 findings. We reported the overall trend in IgG response to SARS-CoV-2 infection, when results
8 among people with persistent symptoms were compared to those without. The trend of each
9 study was classified as a) increase (if \geq one increase reported), b) decrease (if \geq one decrease
10 reported), or c) no increase/decrease (if no increase or decrease reported).

11 Given multiple reports on the same study population, we distinguished between “study
12 population” and “report”, the latter of which refers to each record included in synthesis. We
13 summarized overall associations between serological levels and PCC (as defined by study
14 authors), and sources of inter-study heterogeneity. We presented results stratified by LOC and
15 timing of serological follow-up.

16 **Results**

17 **Study selection and study population characteristics**

18 After removal of duplicates (n=922), we screened 8,018 abstracts and 2,000 full texts, of which
19 29 records (23 study populations) met eligibility criteria and were included in synthesis (**Figure**
20 **1**). **Table 1** summarizes the characteristics of included studies. Studies were published between
21 March 2021 to September 2022 and sample sizes ranged between 51 and 589. Most study
22 populations were “mixed”, i.e., either hospitalized or non-hospitalized during acute illness
23 (n=14), while five were non-hospitalized and three were hospitalized. One study did not specify
24 level of care (LOC) [42], and was hence excluded from synthesis by LOC status (**Tables S1 and**
25 **S2**). We captured severity of acute illness in addition to LOC, though the high variety of scales
26 used to assess severity limited inter-study comparability. We also collected any information on
27 number of symptoms during acute illness, given this feature has been found to be predictive of
28 PCC [18], though these data were available for few study populations (n=4).

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 **5.4.2 Quality assessment**

2 **Tables 2 – 4** display the quality grading of studies according to the NOS. Notably, most
3 prospective cohort studies did not describe efforts to assess the outcome (persistent symptoms)
4 prior to COVID-19 infection (n=15), and follow-up rate was often < 80% or not stated (n=14).
5 Also, only 14 studies controlled for severity or LOC required during acute illness, while 17
6 studies assessed for other potential confounders (e.g., age, sex, pre-existing comorbidities), when
7 assessing relationships between serological markers and PCC.

8 **Persistent sequelae – definitions and subgroups for which serological comparisons available**

9 Any symptoms vs no symptoms post COVID-19 onset

10 Studies used different strategies to define groups with and without persistent symptoms. Most
11 commonly, studies compared findings among subgroups with any symptoms vs no symptoms
12 following acute COVID-19 [29,42-44, 46-56,64]. Most study populations were assessed for PCC
13 between 3 to < 6 months (n=8) or 6 to < 9 months (n=5) post COVID-19. Remaining populations
14 were assessed for symptoms ≥ 12 months (n=4), or between three- and 12-months post COVID-
15 19 (n=1). Some studies assessed PCC at multiple timepoints (**Table 1**).

16 Symptom duration and severity

17 Other studies reported findings based on symptom longevity and intensity of symptoms. A study
18 on a working-age cohort [59] reported average antibody levels over time vs days post COVID-19
19 positive. Another study [45] assessed the association of antibody levels with time to sustained
20 resolution for at least one month among a mixed population. Garcia-Abellan and colleagues [60]
21 administered the COVID-19 symptoms questionnaire (CSQ), asking participants to self-report
22 intensity of symptoms. Participants were classified as symptomatic if their score for any
23 symptoms was in the top quartile of group scores.

24 PCC subtypes and clusters of PCC symptoms

25 Of nine studies to report on the presence or absence of specific symptoms/clusters, two [61,62]
26 assessed for autonomic dysfunction, two [63,64] assessed for neurocognitive deficits, one
27 assessed for sensorimotor impairments [62], three [30,58,65] assessed for fatigue, and two
28 [66,67] assessed for cardiopulmonary symptoms.

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 **Serological results – trends by antibody type and target antigen**

2 Serological results are summarized in **Tables S1 – S3** (by LOC required during acute illness),
3 and **Tables S4 – S6** (by time interval (months) between COVID-19 infection and serological
4 sampling). Below, we describe findings by antibody/target antigen, and discuss inter-study
5 disparities which may have influenced results.

6 IgG response to SARS-CoV-2 nucleocapsid protein (Tables S1 and S4)

7 Of 10 studies that assessed anti-N IgG response, only one controlled for acute disease
8 severity/LOC [56]. Six studies (n=726 participants, **Figures S1a and S1b**) reported no difference
9 in results between those with and without persistent symptoms post COVID-19, which were on
10 mixed (n=2), hospitalized (n=2), and non-hospitalized (n=2) populations (**Figure 2a**). Three
11 studies on mixed populations reported a decrease (n = 3 studies, 212 participants) of anti-N IgG
12 among people with persistent symptoms, as compared to those without. **Figure 3a** displays the
13 trend in anti-N IgG by time interval (months) between COVID-19 infection and serological
14 sampling.

15 IgG response to SARS-CoV-2 Spike protein, S1/S2 subunits, and RBD (Tables S2 and S5)

16 Of 19 studies to assess full or partial anti-Spike IgG response, 10 studies (n=1470 participants,
17 **Figures S1a and S1b**) reported no increase/decrease between people with vs without persisting
18 symptoms. These studies had mixed or hospitalized populations (**Figure 2b**), and most (n = 10)
19 sampled serology < 3 months post-infection (**Figure 3b**). Three studies (459 participants) found
20 increased titres among people with persistent symptoms as compared to those without symptoms,
21 all of which had mixed study populations (**Figure 2b**). Six studies (851 participants) reported ≥ 1
22 decrease in serological results among people with persistent symptoms as compared to those
23 without symptoms, and assessed mixed (n=1), hospitalized (n=3), and non-hospitalized (n=2)
24 populations.

25 Neutralizing antibodies (Tables S3 and S6)

26 Of seven studies to assess neutralizing response, three studies (n=477 participants) reported no
27 difference. Three studies (n=353 participants) reported ≥ 1 decrease. One study (n=293
28 participants) found microneutralizing titres assessed two months post-infection to be positively

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 associated with fatigue score, controlling for severity of acute illness and other covariates.
2 **Figure 3c** displays the trend in neutralizing titres by time interval (months) between COVID-19
3 infection and serological sampling.

4 IgM and IgA response

5 Few studies (n=2; 629 participants) reported on IgM and/or IgA response to SARS-CoV-2
6 antigens, which has been noted previously [68], with respect to PCC status. Anaya et al. [61]
7 compared median (U/mL)/ % of patients anti-RBD IgG, IgA, and IgM between participants with
8 low COMPASS 31 (Composite Autonomic Symptom Score) scores (Cluster 1) as compared to
9 participants with high COMPASS 31 scores (Cluster 2) and found results to be non-significant
10 (p=0.24). Cervia et al. [29] found the log odds of an interaction term between IgM and IgG3 to
11 be negatively associated with persisting symptoms (-2.13, 95% CI -4.45, -0.29) among a mixed
12 population, accounting for covariates.

13 **Vaccination status**

14 Of 13 studies reporting vaccination status, seven reported all participants to be non-vaccinated,
15 and six reported vaccination prior to study recruitment and/or during the study. Of 16 studies to
16 not report vaccination status, most (n=14) recruited participants infected prior to mass-
17 vaccination. Of the six studies to report any vaccination, all participants in five studies were
18 infected prior to mass-vaccination and < 5% of participants in the sixth study completed two
19 vaccine doses prior to baseline visit. Two studies [30,48] compared results for vaccinated and
20 non-vaccinated subgroups.

21 **COVID-19 variant**

22 Only one study reported the COVID-19 strain(s) that infected study participants. Where not
23 specified, we inferred strains to be those which prevailed in the host country of the study during
24 infection or recruitment dates [39]. If these dates were not indicated by the study, we identified
25 the dominant strains to have preceded data collection post-infection. Through this process, we
26 determined that all studies recruited participants to have been infected when wild-type or alpha
27 strains prevailed. Two studies [63,65] may also have recruited participants who were infected
28 when the delta variant was the dominant strain.

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 Discussion

2 As part of the global research response to the pandemic, many studies collected data on humoral
3 response following COVID-19 infection. A subset of these studies also examined for persisting
4 symptoms. Such endeavours demand extensive commitments of time and effort from
5 multidisciplinary research groups, and necessitate substantial funds for study design,
6 implementation, and maintenance. Notably, neutralization assays can be especially costly and
7 labour-intensive [71,72].

8 A multitude of factors can influence PCC and post-infection serological trends. Controlling for
9 potential confounders is a critical prerequisite to establishing the magnitude and direction of
10 relationships between serological markers and PCC [3,8,17,31]. Given the considerable clinical
11 and processing throughput required of eligible studies, large sample sizes with blood draws at
12 multiple timepoints may not be feasible. Pooling of inter-study findings would enable more
13 robust exploration of multiple clinical and serological predictors among varying populations.

14 For these reasons, we performed a rapid review of serological markers which may be associated
15 with PCC, and summarized variations which hampered comparability of inter-study findings.
16 Given substantial heterogeneity in participant characteristics, study procedures, and serological
17 parameters, we were not able to pool results. Upon reviewing overall trends for anti-N IgG, full
18 or partial anti-Spike IgG, and neutralizing response, we inferred the following:

- 19 1. Results suggest no difference in anti-N IgG by PCC status. Studies which reported
20 any increase/decrease were studies with mixed populations that did not account for
21 initial disease severity or LOC. Hence, differences in anti-N IgG response may have
22 been driven by response in the initial phase of illness.
- 23 2. Studies on populations with varying LOC requirements and time intervals of
24 serological sampling ≥ 3 months post-infection (**Figures 3b** and **4b**) reported ≥ 1
25 decrease, when comparing full or partial anti-Spike response among individuals with
26 persisting symptoms to response among individuals without. However, PCC
27 definitions and the analyses and reporting of results were highly variable. Therefore,
28 we can neither refute nor confirm evidence of differences by PCC status.

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

- 1 3. Seven studies assessed neutralizing response. Results were highly variable. Of four
2 studies to report any difference in findings by PCC status, only one study compared
3 results between groups of people with any symptoms vs no symptoms. The remaining
4 three studies assessed for differences by PCC phenotype, severity, or the presence of
5 specific symptoms (e.g., fatigue).
- 6 4. A small subset of studies examined specific symptom(s) or symptom clusters. Further
7 investigation of these findings may elucidate new insights otherwise obscured by use
8 of a blanket definition of PCC. For example, the one study to compare humoral
9 response among groups with and without dyspnea, chest pain, or palpitations reported
10 increased odds of symptoms per doubling of anti-RBD levels, accounting for
11 covariates [66]. Studies to assess fatigue found decreased anti-N IgG among those
12 with severe fatigue as compared to those with non-severe fatigue, and increased risk
13 of fatigue status given higher microneutralizing titres. Finally, the one study to assess
14 neutralizing response among groups with and without a neuropsychiatric phenotype
15 reported decreased neutralizing antibodies among those with symptoms [63].

16 **Recommendations to improve the quality and comparability of evidence**

17 Findings are largely inconclusive as the bulk of evidence failed to account for potential
18 confounders and there are substantial inter-study inconsistencies. We propose the following
19 recommendations to improve the quality and comparability of findings on post-infection
20 serology and PCC:

21 Sharing of serological results collected at common timepoints post-infection, guided by
22 knowledge of expected rates of seroconversion and decay

23 Serological sampling timepoints varied considerably, given no accepted standards [73,74].
24 Results may differ depending on months post-infection at which blood is collected for
25 serological analysis [74-76]. This is especially true if sampling timepoints vary between groups
26 with and without persisting symptoms. We propose that the expected trajectory of
27 immunoglobulins post COVID-19 infection warrants consideration when interpreting serological
28 findings from different post-infection timepoints. Seroconversion for all antibody types occurs
29 on average four to 14 days post-onset [76]. A systematic review of post-infection humoral

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 response found IgG to be detected an average of 12 days post onset, to peak at 25 days, and to
2 start to decline after two months [77]. Seronegative results are more likely prior to 14 days or
3 after six months post-infection [69, 74, 75,76-79]. Target antigen and severity of acute disease
4 may also influence rate of decay [69,74-76]. Multiple studies have found anti-N IgG response to
5 decay more rapidly than response to Spike [74-76]. Furthermore, individuals who experience
6 mild COVID-19 disease are less likely to develop detectable antibodies and more likely to
7 exhibit delayed IgG seroconversion, as compared to those with more severe COVID-19 [80-82].

8 A consensus on analyses and reporting of serological results

9 To better enable harmonization of results from different assays, the WHO's Expert Committee on
10 Biological Standardization developed an International Standard and Reference Panel for SARS-
11 CoV-2 antibodies [82]. Serological findings recalibrated on this standard are reported as binding
12 antibody units (BAU/mL). However, some studies have found differences in recalibrated results
13 derived from different assays [73,83]. Additionally, variable derivation of cut-offs and thresholds
14 and units of quantitative results obscure understanding of findings. Studies that report strength of
15 response using cut-offs (e.g., low, medium, or high titres) should delineate cut-offs as pre-
16 specified or exploratory, and explain how they were derived [76-78]. Also, endeavours to assess
17 serological decay may only state whether or not there was a difference in results over time:
18 absolute values should be reported to improve transparency and comprehension of findings.
19 Finally, given the importance of collaboration across multiple disciplines to advance knowledge
20 on PCC, there is great need for clear communication and shared understanding around the
21 meaning and limitations of findings [76-78,84].

22 More reports on specific PCC symptoms and symptom clusters

23 Knowledge of PCC continues to evolve, as do the definitions for this condition and subtypes
24 based on varying severity or character of symptoms [1-4,6]. The exploration of PCC subtypes is
25 an important and emerging topic, with potential to advance our understanding of
26 pathophysiological mechanisms and markers, and better enable health systems to identify and
27 address key care needs [6,84]. However, there continues to be poor consensus on what these
28 subtypes are, and how clinical characteristics and COVID-19 variants may influence the
29 manifestation and severity of different symptom patterns [6,33,85,86]. More reports on subtypes

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 and potential biomarkers may yield new findings which illuminate PCC etiology, detection, and
2 treatment.

3 Risk of bias – recommendations to improve the quality of evidence

4 Common factors threatening study quality included failures to describe efforts to confirm that
5 SARS-CoV-2 infection preceded the outcome, and to control for potential confounders. We
6 identified acute severity of illness as the most important confounder to consider, given that
7 substantial evidence has highlighted this to be a major driver of serological response
8 [69,70,73,76,81,87], and many studies have found more severe illness early on to be predictive
9 of PCC onset and trajectory [15,16,20,88].

10 Some studies also restricted serological follow-up to seropositive cases. This strategy may have
11 biased results towards the null. Results are more likely to have been influenced if seropositivity
12 was determined prior to the generation of detectable antibodies post-infection, or after antibodies
13 and sensitivity begin to diminish, depending on assay and severity of acute illness [74].

14 **Strengths and limitations**

15 Key strengths of this review include the large volume of reports assessed for eligibility, and
16 careful consideration and thorough description of a wide array of factors which limit inter-study
17 comparability. Also, we reported findings among different PCC subtypes, currently an important
18 and growing area of research interest [85]. However, several limitations warrant consideration.
19 First, we noted restricted variation in terms of COVID-19 strain and vaccination status. The
20 majority of participants from all studies were infected by wildtype/alpha strains, and vaccine
21 naive at time of infection. Therefore, there was limited opportunity to explore the effects of
22 hybrid immunity and different variants of concern on findings. Second, the literature on PCC and
23 COVID-19 immune response continues to evolve; evidence published after our search date in
24 October 2022 may yield different findings. Third, given variations in serological response and
25 PCC presentation among children, we chose to focus this review on adult COVID-19 survivors
26 [89,90]. Therefore, our results are not generalizable to younger age groups. Fourth, the synthesis
27 only focused on IgG response to SARS-CoV-2 antigens and measures of neutralizing efficiency.
28 Other potential biomarkers were not explored. Fifth, we acknowledge the risk of survivor bias,
29 especially among studies on hospitalized populations. Ozonoff et al. [46] found that patients who

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

1 died during acute illness had lower antibody titres than survivors, many of whom went on to be
2 assessed ≥ 12 weeks post-infection. Sixth, this review focused on self-reported symptoms and
3 severity. While this approach integrates the patient perspective, there is risk of reporting bias.
4 Finally, we did not assess for effects from COVID-19 re-infections.

5 **Conclusion**

6 Examination of PCC onset and phenotype as functions of serological predictors, accounting for
7 clinical covariates, may yield emergent insights and advance understanding of PCC etiology,
8 detection, and treatment. As the assessment of COVID-19 humoral response is not a standard
9 practice in healthcare settings, serological results by PCC status have been made available
10 through international research efforts. However, given poor consensus on standards of clinical
11 and serological collection, analysis, and reporting, there are substantial inter-study
12 inconsistencies. Uniform efforts to harmonize reporting of serological results and control for
13 acute disease severity or level of care requirements would improve the quality, comparability,
14 and comprehension of findings. There is also continued need for reports on PCC subtypes, an
15 important and evolving topic with potential to advance understanding of pathophysiological
16 mechanisms and markers, and better enable health systems to identify and address key care
17 needs. Finally, future reviews of ongoing studies will facilitate more detailed analyses of the
18 effects of SARS-CoV-2 vaccination and variants on findings.

19 **Acknowledgements:** The search strategy was developed with assistance from the Canadian
20 Health Library.

21 **Author contributions:** EC and JL drafted the manuscript. EP assisted screening, data extraction,
22 and risk of bias assessment. CG, SH, and MAL provided expertise on epidemiological and
23 serological content. All authors critically reviewed and approved the final manuscript.

24 **Funding:** EC is supported by the AI4PH Scholarship Program, funded by CIHR (Canadian
25 Institutes of Health Research - Instituts de recherche en santé du Canada).

26 **Competing interests:** None declared

27 **Data availability:** All relevant data are within the manuscript. No additional source data are
28 required.

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

References

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
1. World Health Organization. Post COVID-19 Condition. Available at: <https://www.who.int/teams/health-care-readiness/post-covid-19-condition>
 2. Public Health Agency of Canada. Post-COVID-19 condition (long COVID). Published August 20, 2021. Available at: <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html>
 3. Post COVID-19 Condition in Canada: What we know, what we don't know, and a framework for action. Published May 17, 2023. Available at: <https://science.gc.ca/site/science/en/office-chief-science-advisor/initiatives-covid-19/post-covid-19-condition-canada-what-we-know-what-we-dont-know-and-framework-action>
 4. COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("Long COVID") - UpToDate. Published June 19, 2023. Available at: <https://www.uptodate.com/contents/covid-19-evaluation-and-management-of-adults-with-persistent-symptoms-following-acute-illness-long-covid>
 5. Spiers N. Reassessment of persistent symptoms, self-reported COVID-19 infection and SARS-CoV-2 serology in the SAPRIS-SERO cohort: identifying possible sub-syndromes of Long Covid. medRxiv. Published March 28, 2022. doi:10.1101/2022.02.25.22271499
 6. Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. *Reviews in medical virology*. 2022;32(4). doi:10.1002/rmv.2315
 7. Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. *Trends in Endocrinology & Metabolism*. 2023;34(6):321-344. doi:10.1016/j.tem.2023.03.002
 8. O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. *eClinicalMedicine*. 2023;55. doi:10.1016/j.eclinm.2022.101762
 9. Ballouz T, Menges D, Anagnostopoulos A, et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. *BMJ*. 2023;381. doi:10.1136/bmj-2022-074425
 10. Kim Y, Bae S, Chang HH, Kim SW. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. *Sci Rep*. 2023;13(1):1-9. doi:10.1038/s41598-023-36995-4
 11. Gualano MR, Rossi MF, Borrelli I, et al. Returning to work and the impact of post COVID-19 condition: A systematic review. *Work*. 2022;73(2):405-413. doi:10.3233/WOR-220103
 12. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol*. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2
 13. Faghy MA, Maden-Wilkinson T, Arena R, et al. COVID-19 patients require multi-disciplinary rehabilitation approaches to address persisting symptom profiles and restore

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

- 1 pre-COVID quality of life. *Expert Review of Respiratory Medicine*. Published April 18,
2 2022. Available at:
3 <https://www.tandfonline.com/doi/abs/10.1080/17476348.2022.2063843>
- 4 14. Yong SJ, Halim A, Halim M, et al. Inflammatory and vascular biomarkers in post-
5 COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers.
6 *Reviews in Medical Virology*. 2023;33(2):e2424. doi:10.1002/rmv.2424
- 7 15. Boaventura P, Macedo S, Ribeiro F, Jaconiano S, Soares P. Post-COVID-19 Condition:
8 Where Are We Now? *Life*. 2022;12(4):517. doi:10.3390/life12040517
- 9 16. Mantovani A, Morrone MC, Patrono C, et al. Long Covid: where we stand and
10 challenges ahead. *Cell Death Differ*. 2022;29(10):1891-1900. doi:10.1038/s41418-022-
11 01052-6
- 12 17. Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of
13 long COVID. *Nat Rev Immunol*. Published July 11, 2023:1-17. doi:10.1038/s41577-023-
14 00904-7
- 15 18. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat*
16 *Med*. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
- 17 19. Sarri G, Liu W, Zobotka L, et al. Prognostic Factors of COVID-19: An Umbrella Review
18 Endorsed by the International Society for Pharmacoepidemiology. *Clinical Pharmacology*
19 *& Therapeutics*. Published July 20, 2023. doi:10.1002/cpt.2977
- 20 20. Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk Factors Associated With Post-
21 COVID-19 Condition: A Systematic Review and Meta-analysis. *JAMA internal*
22 *medicine*. 2023;183. doi:10.1001/jamainternmed.2023.0750
- 23 21. Chen B, Julg B, Mohandas S, Bradfute SB, Force RMPT. Viral persistence, reactivation,
24 and mechanisms of long COVID. *eLife*. 2023;12. doi:10.7554/eLife.86015
- 25 22. Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship
26 between changes in symptoms and antibody titers after a single vaccination in patients
27 with Long COVID. *Journal of Medical Virology*. 2022;94(7):3416-3420.
28 doi:10.1002/jmv.27689
- 29 23. Kervecan J, Staropoli I, Slama D, et al. Divergent adaptive immune responses define two
30 types of long COVID. *Front Immunol*. 2023;14:1221961.
31 doi:10.3389/fimmu.2023.1221961
- 32 24. Opsteen S, Files JK, Fram T, Erdmann N. The role of immune activation and antigen
33 persistence in acute and long COVID. *Journal of Investigative Medicine*. 2023;71(5):545.
34 doi:10.1177/10815589231158041
- 35 25. Joung S, Weber B, Wu M, et al. Serological response to vaccination in post-acute
36 sequelae of COVID. *BMC Infect Dis*. 2023;23(1):1-9. doi:10.1186/s12879-023-08060-y
- 37 26. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent Circulating Severe Acute
38 Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus
39 Disease 2019 Sequelae. *Clin Infect Dis*. 2023;76(3):e487-e490. doi:10.1093/cid/ciac722
- 40 27. Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID identified
41 through immune profiling. *medRxiv*. Published August 10, 2022.
42 doi:10.1101/2022.08.09.22278592

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

- 1 28. García-Abellán J, Fernández M, Padilla S, et al. Immunologic phenotype of patients with
2 long-COVID syndrome of 1-year duration. *Front Immunol.* 2022;13:920627.
3 doi:10.3389/fimmu.2022.920627
- 4 29. Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of
5 post-acute COVID-19 syndrome. *Nat Commun.* 2022;13(1):1-12. doi:10.1038/s41467-
6 021-27797-1
- 7 30. Varnai R, Molnar T, Zavori L, et al. Serum Level of Anti-Nucleocapsid, but Not Anti-
8 Spike Antibody, Is Associated with Improvement of Long COVID Symptoms. *Vaccines.*
9 2022;10(2):165. doi:10.3390/vaccines10020165
- 10 31. Comparability of Control and Comparison Groups in Studies Assessing Long COVID.
11 *The American Journal of Medicine.* Published online January 25, 2023.
12 doi:10.1016/j.amjmed.2023.01.005
- 13 32. Du M, Ma Y, Deng J, Liu M, Liu J. Comparison of Long COVID-19 Caused by Different
14 SARS-CoV-2 Strains: A Systematic Review and Meta-Analysis. *International Journal of*
15 *Environmental Research and Public Health.* 2022;19(23). doi:10.3390/ijerph192316010
- 16 33. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID
17 associated with delta versus omicron variants of SARS-CoV-2. *The Lancet.*
18 2022;399(10343):2263-2264. doi:10.1016/S0140-6736(22)00941-2
- 19 34. Spinicci M, Graziani L, Tilli M, et al. Infection with SARS-CoV-2 Variants Is Associated
20 with Different Long COVID Phenotypes. *Viruses.* 2022;14(11):2367.
21 doi:10.3390/v14112367
- 22 35. Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk
23 of developing long-COVID and on existing long-COVID symptoms: A systematic
24 review. *eClinicalMedicine.* 2022;53. doi:10.1016/j.eclinm.2022.101624
- 25 36. Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination
26 on long covid: systematic review. *BMJ Medicine.* 2023;2(1). doi:10.1136/bmjmed-2022-
27 000385
- 28 37. Rapid Reviews Methods Group | Cochrane Methods. Published January 6, 2016.
29 Available at: <https://methods.cochrane.org/news/rapid-reviews-methods-group>
- 30 38. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic
31 reviews and meta-analyses: the PRISMA statement. *BMJ.* 2009;339.
32 doi:10.1136/bmj.b2535
- 33 39. Our World in Data. SARS-CoV-2 variants in analyzed sequences. Available at:
34 <https://ourworldindata.org/grapher/covid-variants-area>
- 35 40. Johns Hopkins Coronavirus Resource Center. Published March 10, 2023. Available at:
36 <https://coronavirus.jhu.edu/vaccines/international>
- 37 41. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale
38 (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 2011.
39 Available at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- 40 42. Bilich T, Nelde A, Heitmann JS, et al. T cell and antibody kinetics delineate SARS-CoV-
41 2 peptides mediating long-term immune responses in COVID-19 convalescent
42 individuals. *Science Translational Medicine.* Published April 21, 2021.
43 doi:10.1126/scitranslmed.abf7517

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

- 1 43. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised
2 patients with COVID-19: a longitudinal prospective cohort study. *The Lancet regional*
3 *health Europe*. 2021;6. doi:10.1016/j.lanepe.2021.100122
- 4 44. Gerhards C, Thiaucourt M, Kittel M, et al. Longitudinal assessment of anti-SARS-CoV-2
5 antibody dynamics and clinical features following convalescence from a COVID-19
6 infection. *Int J Infect Dis*. 2021;107:221-227. doi:10.1016/j.ijid.2021.04.080
- 7 45. Jia X, Cao S, Lee AS, et al. Anti-nucleocapsid antibody levels and pulmonary comorbid
8 conditions are linked to post-COVID-19 syndrome. *JCI insight*. 2022;7(13).
9 doi:10.1172/jci.insight.156713
- 10 46. Ozonoff A, Schaenman J, Jayavelu ND, et al. Phenotypes of disease severity in a cohort
11 of hospitalized COVID-19 patients: Results from the IMPACC study. *EBioMedicine*.
12 2022;83. doi:10.1016/j.ebiom.2022.104208
- 13 47. Peghin M, Palese A, Venturini M, et al. Post-COVID-19 symptoms 6 months after acute
14 infection among hospitalized and non-hospitalized patients. *Clinical microbiology and*
15 *infection : the official publication of the European Society of Clinical Microbiology and*
16 *Infectious Diseases*. 2021;27(10). doi:10.1016/j.cmi.2021.05.033
- 17 48. Peghin M, Martino MD, Palese A, et al. Post-COVID-19 syndrome and humoral
18 response association after 1 year in vaccinated and unvaccinated patients. *Clinical*
19 *Microbiology and Infection*. 2022;28(8):1140. doi:10.1016/j.cmi.2022.03.016
- 20 49. Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune
21 and inflammatory responses in individuals recovering from COVID-19 with and without
22 post-acute symptoms. *Cell Reports*. 2021;36(6):109518.
23 doi:10.1016/j.celrep.2021.109518
- 24 50. Peluso MJ, Lu S, Tang AF, et al. Markers of Immune Activation and Inflammation in
25 Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus
26 2 Infection. *J Infect Dis*. 2021;224(11):1839-1848. doi:10.1093/infdis/jiab490
- 27 51. Pilmis B, Elkaibi I, Ponfilly GP de, et al. Evolution of anti-SARS-CoV-2 immune
28 response in a cohort of French healthcare workers followed for 7 months. *Infectious*
29 *Diseases Now*. 2022;52(2):68. doi:10.1016/j.idnow.2022.01.004
- 30 52. Seeßle J, Waterboer T, Hippchen T, et al. Persistent Symptoms in Adult Patients 1 Year
31 After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. *Clin Infect*
32 *Dis*. 2022;74(7):1191-1198. doi:10.1093/cid/ciab611
- 33 53. Sneller MC, Liang CJ, Marques AR, et al. A Longitudinal Study of COVID-19 Sequelae
34 and Immunity: Baseline Findings. *Annals of Internal Medicine*. Published online May 24,
35 2022. doi:10.7326/M21-4905
- 36 54. Sonnweber T, Tymoszek P, Sahanic S, et al. Investigating phenotypes of pulmonary
37 COVID-19 recovery: A longitudinal observational prospective multicenter trial. *eLife*.
38 2022;11. doi:10.7554/eLife.72500
- 39 55. Wynberg E, Han AX, Boyd A, et al. The effect of SARS-CoV-2 vaccination on post-
40 acute sequelae of COVID-19 (PCC): A prospective cohort study. *Vaccine*.
41 2022;40(32):4424-4431. doi:10.1016/j.vaccine.2022.05.090

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

- 1 56. Zhan Y, Zhu Y, Wang S, et al. SARS-CoV-2 immunity and functional recovery of
2 COVID-19 patients 1-year after infection. *Sig Transduct Target Ther.* 2021;6(1):1-12.
3 doi:10.1038/s41392-021-00777-z
- 4 57. Díaz-Salazar S, Navas R, Sainz-Maza L, et al. Blood group O is associated with post-
5 COVID-19 syndrome in outpatients with a low comorbidity index. *Infectious Diseases.*
6 Published August 27, 2022. Available at:
7 <https://www.tandfonline.com/doi/abs/10.1080/23744235.2022.2115548>
- 8 58. Blomberg B, Mohn KGI, Brokstad KA, et al. Long COVID in a prospective cohort of
9 home-isolated patients. *Nat Med.* 2021;27(9):1607-1613. doi:10.1038/s41591-021-
10 01433-3
- 11 59. Horton DB, Barrett ES, Roy J, et al. Determinants and Dynamics of SARS-CoV-2
12 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study. *J*
13 *Infect Dis.* 2021;224(8):1345-1356. doi:10.1093/infdis/jiab411
- 14 60. García-Abellán J, Padilla S, Fernández-González M, et al. Antibody Response to SARS-
15 CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a
16 Longitudinal Study. *Journal of clinical immunology.* 2021;41(7). doi:10.1007/s10875-
17 021-01083-7
- 18 61. Anaya JM, Rojas M, Salinas ML, et al. Post-COVID syndrome. A case series and
19 comprehensive review. *Autoimmunity reviews.* 2021;20(11).
20 doi:10.1016/j.autrev.2021.102947
- 21 62. Wahlgren C, Divanoglou A, Larsson M, et al. Rehabilitation needs following COVID-19:
22 Five-month post-discharge clinical follow-up of individuals with concerning self-reported
23 symptoms. *eClinicalMedicine.* 2022;43. doi:10.1016/j.eclinm.2021.101219
- 24 63. Lier J, Stoll K, Obrig H, et al. Neuropsychiatric phenotype of post COVID-19 syndrome
25 in non-hospitalized patients. *Front Neurol.* 2022;13:988359.
26 doi:10.3389/fneur.2022.988359
- 27 64. Peluso MJ, Sans HM, Forman CA, et al. Plasma Markers of Neurologic Injury and
28 Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-
29 CoV-2 Infection. *Neurology - Neuroimmunology Neuroinflammation.* 2022;9(5).
30 doi:10.1212/NXI.0000000000200003
- 31 65. Molnar T, Varnai R, Schranz D, et al. Severe Fatigue and Memory Impairment Are
32 Associated with Lower Serum Level of Anti-SARS-CoV-2 Antibodies in Patients with
33 Post-COVID Symptoms. *Journal of clinical medicine.* 2021;10(19).
34 doi:10.3390/jcm10194337
- 35 66. Durstenfeld MS, Peluso MJ, Kelly JD, et al. Role of antibodies, inflammatory markers,
36 and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-
37 CoV-2 infection. *JCI insight.* 2022;7(10). doi:10.1172/jci.insight.157053
- 38 67. Stavileci B, Özdemir E, Özdemir B, et al. De-novo development of fragmented QRS
39 during a six-month follow-up period in patients with COVID-19 disease and its cardiac
40 effects. *Journal of Electrocardiology.* 2022;72:44-48.
41 doi:10.1016/j.jelectrocard.2022.02.012

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

- 1 68. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in
2 humans: A systematic review. *PLOS ONE*. 2020;15(12):e0244126.
3 doi:10.1371/journal.pone.0244126
- 4 69. Knies A, Ladage D, Braun RJ, Kimpel J, Schneider M. Persistence of humoral response
5 upon SARS-CoV-2 infection. *Reviews in Medical Virology*. 2022;32(2):e2272.
6 doi:10.1002/rmv.2272
- 7 70. Sancilio A, Schrock JM, Demonbreun AR, et al. COVID-19 symptom severity predicts
8 neutralizing antibody activity in a community-based serological study. *Sci Rep*.
9 2022;12(1):1-7. doi:10.1038/s41598-022-15791-6
- 10 71. Winichakoon P, Wipasa J, Chawansuntati K, et al. Diagnostic performance between in-
11 house and commercial SARS-CoV-2 serological immunoassays including binding-
12 specific antibody and surrogate virus neutralization test (sVNT). *Sci Rep*. 2023;13(1):34.
13 doi:10.1038/s41598-022-26202-1
- 14 72. Bayarri-Olmos R, Idorn M, Rosbjerg A, et al. SARS-CoV-2 Neutralizing Antibody
15 Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. *J*
16 *Immunol*. 2021;207(3):878-887. doi:10.4049/jimmunol.2100272
- 17 73. Egger AE, Sahanic S, Gleiss A, et al. One-Year Follow-Up of COVID-19 Patients
18 Indicates Substantial Assay-Dependent Differences in the Kinetics of SARS-CoV-2
19 Antibodies. *Microbiology Spectrum*. Published October 12, 2022.
20 doi:10.1128/spectrum.00597-22
- 21 74. Torres Ortiz A, Fenn Torrente F, Twigg A, et al. The influence of time on the sensitivity
22 of SARS-CoV-2 serological testing. *Sci Rep*. 2022;12(1):1-8. doi:10.1038/s41598-022-
23 14351-2
- 24 75. Zheng X, Duan R hua, Gong F, et al. Accuracy of serological tests for COVID-19: A
25 systematic review and meta-analysis. *Front Public Health*. 2022;10:923525.
26 doi:10.3389/fpubh.2022.923525
- 27 76. Charlton CL, Kanji JN, Tran V, et al. on behalf of the Canadian Public Health Laboratory
28 Network (CPHLN) Serology Working Group. Practical guidance for clinical laboratories
29 for SARS-CoV-2 serology testing. *Commun Dis Rep* 2021;47(4):171–83.
30 <https://doi.org/10.14745/ccdr.v47i04a01>
- 31 77. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody Response After SARS-
32 CoV-2 Infection and Implications for Immunity. *Annals of Internal Medicine*. Published
33 March 16, 2021. doi:10.7326/M20-7547
- 34 78. Karger AB, Brien JD, Christen JM, et al. The Serological Sciences Network (SeroNet)
35 for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay
36 Harmonization. *mSphere*. Published June 15, 2022. doi:10.1128/msphere.00193-22
- 37 79. Chivese T, Matiznadzo JT, Musa OAH, et al. The prevalence of adaptive immunity to
38 COVID-19 and reinfection after recovery – a comprehensive systematic review and
39 meta-analysis. *Pathogens and Global Health*. Published January 31, 2022.
40 <https://www.tandfonline.com/doi/abs/10.1080/20477724.2022.2029301>
- 41 80. Elslande JV, Oyaert M, Lorent N, et al. Lower persistence of anti-nucleocapsid compared
42 to anti-spike antibodies up to one year after SARS-CoV-2 infection. *Diagnostic*

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

- 1 Microbiology and Infectious Disease. 2022;103(1):115659.
2 doi:10.1016/j.diagmicrobio.2022.115659
- 3 81. Van den Hoogen LL, Smits G, van Hagen CCE, et al. Seropositivity to Nucleoprotein to
4 detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect
5 breakthrough infections after COVID-19 vaccination? *Vaccine*. 2022;40(15):2251-2257.
6 doi:10.1016/j.vaccine.2022.03.009
- 7 82. Knezevic I, Mattiuzzo G, Page M, et al. WHO International Standard for evaluation of
8 the antibody response to COVID-19 vaccines: call for urgent action by the scientific
9 community. *Lancet Microbe*. 2022;3(3):e235-e240. doi:10.1016/S2666-5247(21)00266-4
- 10 83. Whitaker HJ, Gower C, Otter AD, et al. Nucleocapsid antibody positivity as a marker of
11 past SARS-CoV-2 infection in population serosurveillance studies: impact of variant,
12 vaccination, and choice of assay cut-off. medRxiv. Published October 26, 2021:
13 doi:10.1101/2021.10.25.21264964
- 14 84. Steenhuis M, Wouters E, Schrezenmeier H, et al. Quality assessment and harmonization
15 of laboratories across Europe for multiple SARS-CoV-2 serology assays. *Vox Sanguinis*.
16 Published July 4, 2023. doi:10.1111/vox.13480
- 17 85. Basharat S, Chao YS, McGill SC. Subtypes of Post-COVID-19 Condition: A Review of
18 the Emerging Evidence. *cjht*. 2022;2(12). doi:10.51731/cjht.2022.516
- 19 86. Canas LS, Molteni E, Deng J, et al. Profiling post-COVID-19 condition across different
20 variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type,
21 unvaccinated alpha-variant, and vaccinated delta-variant populations. *The Lancet Digital
22 Health*. 2023;5(7):e421-e434. doi:10.1016/S2589-7500(23)00056-0
- 23 87. Yaugel-Novoa M, Bourlet T, Paul S. Role of the humoral immune response during
24 COVID-19: guilty or not guilty? *Mucosal Immunology*. 2022;15(6):1170.
25 doi:10.1038/s41385-022-00569-w
- 26 88. Wong MCS, Huang J, Wong YY, et al. Epidemiology, Symptomatology, and Risk
27 Factors for Long COVID Symptoms: Population-Based, Multicenter Study. *JMIR Public
28 Health and Surveillance*. 2023;9(1):e42315. doi:10.2196/42315
- 29 89. Jacobsen EM, Fabricius D, Class M, et al. High antibody levels and reduced cellular
30 response in children up to one year after SARS-CoV-2 infection. *Nat Commun*.
31 2022;13(1):1-16. doi:10.1038/s41467-022-35055-1
- 32 90. Morello R, Martino L, Buonsenso D. Diagnosis and management of post-COVID (Long
33 COVID) in children: a moving target. *Current Opinion in Pediatrics*. 2023;35(2):184.
34 doi:10.1097/MOP.0000000000001221




Figure 1: PRISMA diagram

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

Figure 2 (a-c): Trends in serological response among groups with persistent symptoms as compared to groups without persistent symptoms, by level of care (LOC) requirements during acute illness




Figure 2a: Trend in anti-N IgG by level of care (LOC) requirements during acute illness - number of studies to report any decrease, any increase, or no increase/decrease in anti-N IgG response among people with persistent symptom(s), as compared to people without persistent symptom(s). Of nine studies to assess anti-N IgG, two had hospitalized populations and two had non-hospitalized populations, all of which reported no increase/decrease. Of five studies with mixed populations to assess anti-N IgG, three studies reported ≥ 1 decrease and two studies reported no increase/decrease. One study [42] did not specify LOC and was hence excluded.

Figure 2b: Trend in anti-Spike IgG by level of care (LOC) requirements during acute illness - number of studies to report any decrease, any increase, or no increase/decrease in partial or full anti-Spike IgG response among people with persistent symptom(s), as compared to people without persistent symptom(s). Of 19 studies to assess full or partial anti-Spike IgG, four had hospitalized populations, of which one reported no increase/decrease, and three reported ≥ 1 decrease. Two studies had non-hospitalized populations, both of which reported ≥ 1 decrease. Finally, 12 studies had mixed populations, of which three reported ≥ 1 increase, one reported ≥ 1 decrease, and eight reported no increase/decrease. One study [42] did not specify LOC and was hence excluded.

Figure 2c: Trend in neutralizing response by level of care (LOC) requirements during acute illness - number of studies to report any decrease, any increase, or no increase/decrease in neutralizing response among people with persistent symptom(s), as compared to people without persistent symptom(s). Of seven studies to assess neutralizing response, two had hospitalized populations and one had a non-hospitalized population, all of which reported ≥ 1 decrease. The remaining four studies had mixed populations, one of which reported ≥ 1 increase with the remainder reporting no increase/decrease.

Figure 3 (a-c): Trends in serological response among groups with persistent symptoms as compared to groups without persistent symptoms, time interval (months) between COVID-19 infection and serological sampling




Figure 3a: Trend in anti-N IgG by time interval (months) between COVID-19 infection and serological sampling - number of studies to report any decrease, any increase, or no increase/decrease in anti-N IgG response among people with persistent symptom(s), as compared to people without persistent symptom(s). Five studies assessed anti-N IgG <3 months post COVID-19, of which four reported no increase/decrease, and one reported ≥ 1 decrease. Four studies assessed anti-N IgG ≥ 3 months to <6 months post COVID-19, of which two reported no increase/decrease, one reported ≥ 1 increase, and one reported ≥ 1 decrease. Four studies assessed anti-N IgG ≥ 6 months to <9 months post COVID-19, of which three reported no increase/decrease, and one reported ≥ 1 decrease. Finally, one study assessed anti-N IgG ≥ 9 months to

Figure 3b: Trend in anti-Spike IgG by time interval (months) between COVID-19 infection and serological sampling - number of studies to report any decrease, any increase, or no increase/decrease in partial or full anti-Spike IgG response among people with persistent symptom(s), as compared to people without persistent symptom(s). Ten studies assessed serology <3 months post COVID-19, of which one reported ≥ 1 increase and nine reported no increase/decrease. Eight studies assessed serology ≥ 3 months to <6 months post COVID-19, of which two reported ≥ 1 increase, two reported ≥ 1 decrease, and four reported no increase/decrease. Five studies assessed serology ≥ 6 months to <9 months post COVID-19, of which two reported ≥ 1 decrease, and three reported no increase/decrease. One study assessed serology ≥ 9

Figure 3c: Trend in neutralizing response by time interval (months) between COVID-19 infection and serological sampling - number of studies to report any decrease, any increase, or no increase/decrease in neutralizing response among people with persistent symptom(s), as compared to people without persistent symptom(s). Three studies assessed neutralizing response <3 months post COVID-19, of which two reported no increase/decrease, and one reported ≥ 1 increase. Two studies assessed neutralizing response ≥ 3 months to <6 months post COVID-19, of which both reported no increase/decrease. Two studies assessed neutralizing response ≥ 6 months to <9 months post COVID-19, of which one reported no increase/decrease increase/decrease and one reported ≥ 1 decrease. Finally, three studies assessed

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

12 months post COVID-19 and reported no increase/decrease. In studies with multiple timepoints of assessment, all results reported ≥ 12 weeks were included.

months up to 12 months post COVID-19, which reported ≥ 1 decrease. In studies with multiple timepoints of assessment, all results reported ≥ 12 weeks were included.

neutralizing response ≥ 9 months to 12 months post COVID-19, of which one reported no increase/decrease, and two reported ≥ 1 decrease. In studies with multiple timepoints of assessment, all results reported ≥ 12 weeks were included.

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

Table 1: Characteristics of included studies (n=23 – 19 studies are of prospective cohort design; the design of the other four studies are indicated in footnotes)

Population ^{a,b} (Region / Country)	Publication date	Follow up period(s) for persistent sequelae	Study size	Participant characteristics			Acute phase of illness		
				Age (mean, SD or median, IQR)	Male, N (%)	Pre-existing comorbidities, N (%) and median (IQR)	Level of care, N (%)	Severity of disease	Number of symptoms
Bogotá / Columbia [61]* With low COMPASS 31	November 2021	Median 219 (IQR 115) days post onset	---	---	---	---	---	---	---
With high COMPASS 31			69	50 (14.0)	35 (50.7)	Median BMI 28.0 (IQR 5.0); COPD 1 (1.4), asthma 0 (0.0); cancer 0 (0.0); type 2 diabetes 10 (14.5); hypertension 12 (17.4); CAD 0 (0)	Non-hospitalized 26 (37.7); hospitalized 43 (62.3); ICU 15 (21.7)	NR	NR
			31	48 (18.5)	12 (38.7)	Median BMI 28.1 (IQR 6.4); COPD 0 (0.0), asthma 0 (0.0); cancer 1 (3.2); type 2 diabetes 5 (16.1); hypertension 5 (16.1); CAD 0 (0)	Non-hospitalized 9 (29.0); hospitalized 22 (71.0); ICU 9 (29.0)	NR	NR
Cologne / Germany [43] With persistent sequelae	July 2021	Median 131 days (IQR 37); median 207 days (IQR 47) post onset	---	---	---	---	---	---	---
Without persistent sequelae			123	47 (23.0)	39 (31.7)	Any preconditions 31 (26.3)	All non-hospitalized	NR	Median (IQR) 5 (3)
			230	49 (21.0)	112 (48.7)	Any preconditions 63 (28.8)	Non-hospitalized 222 (96.5); hospitalized 8 (3.6)	NR	Median (IQR) 4 (3)
Tübingen / Germany [42]	March 2021	Median 159 days post infection	51	44, range 21 - 66	25 (49.0)	NR	NR	All had mild or moderate COVID-19 infection	NR
Bergen / Norway [58] Fatigue	June 2021	6 (±1) months post illness	---	---	---	---	---	---	---
			108	52 (24.0)	44 (40.7)	Asthma/COPD 23 (21.3); median BMI 25.3 IQR (4.6); diabetes 6 (5.6); hypertension 17 (15.7); chronic heart disease 13 (12.0); immunosuppression 6 (5.6); any comorbidity 62 (57.4)	Non-hospitalized 69 (63.9); hospitalized 39 (36.1)	Asymptomatic 2 (1.9); median severity of illness 2 (IQR 2.0)	NR

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

No fatigue			185	45 (27.0)	99 (53.5)	Asthma/COPD 14 (7.6); median BMI 24.7 IQR (4.2); diabetes 7 (3.8); hypertension 17 (9.2); chronic heart disease 8 (4.3); immunosuppression 4 (2.2); any comorbidity 71 (38.4)	Non-hospitalized 162 (87.6); hospitalized 23 (12.4)	Asymptomatic 1 (0.5); median severity of illness 2 (IQR 0.0)	NR
Zurich / Switzerland [29]	January 2022	---	---	---	---	---	---	---	---
Derivation cohort		At least 3.5 months (105 days) post onset	134	43 (34.0)	75 (56.0)	Lung disease 21 (15.7), including asthma 17 (12.7); median BMI for mild cases 25 (IQR 4.0), for severe cases 28 (IQR 6.0); diabetes 19 (14.2); cardiovascular disease 18 (13.4); hypertension 31 (23.1); malignancy 8 (6.0); systematic immunosuppression 9 (6.7)	Non-hospitalized 80 (59.7); hospitalized 54 (40.3)	89 (66.4) mild and 45 (33.6) severe COVID-19 cases	Median 2 (IQR 2.0)
Validation cohort		6 months post diagnosis	395	51 (33.0)	199 (50.4)	Lung disease 29 (7.3), including asthma 12 (3.1); median BMI 24 (IQR 4.0); diabetes 7 (1.8); cardiovascular disease 20 (5.1); hypertension 54 (13.7); malignancy 22 (5.6); systematic immunosuppression 10 (2.5)	Non-hospitalized 378 (95.7); hospitalized 17 (4.3)	386 (97.7) mild and 9 (2.3) severe COVID-19 cases	Median 2 (IQR 2.0)
Cantabria / Spain [57]***	August 2022	3 months (median 115 days)	---	---	---	---	---	---	---
With persistent sequelae			36	47 (14.0)	11 (30.6)	Asthma 5 (13.8); diabetes 1 (2.7); mean BMI 24.7 (SD 4.0); obesity 3 (8.3); hypertension 4 (11.1); ischemic heart disease 2 (5.5); immunosuppression 1 (2.7); mean CCI 0.20 (SD 0.4); CCI score: 0, 28 (77.7); 1, 7 (20); 2+, 0 (0)	All non-hospitalized	All had mild COVID-19 infection	---

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

Without persistent sequelae			85	45 (17.0)	42 (49.4)	Asthma 6 (7.0); diabetes 5 (5.8); mean BMI 25.6 (SD 3.0); obesity 12 (14.1); hypertension 17 (20.0); ischemic heart disease 4 (4.7); immunosuppression 2 (2.3); CCI mean 0.48 (SD 0.8); CCI score: 0, 56 (65.8); 1, 24 (28.2); 2+, 2 (2.3)	All non-hospitalized	All had mild COVID-19 infection	---
Alicante / Spain [28,60] With persistent sequelae	August 2022	6 and 12 months post discharge	---	---	---	---	---	---	---
			14	60 (18.0)	5 (35.7)	COPD 0 (0); diabetes 3 (21.4); cardiovascular disease 3 (21.4); hypertension 8 (57.1); cancer 0 (0); autoimmune diseases 1 (7.1); any comorbidity 10 (71.4); median CCI 2 (IQR 2.5)	All hospitalized; ICU 4 (28.6)	WHO Severity Score: 3, 9 (64.3); 4, 1 (7.1); 5, 0 (0); 6, 4 (28.6)	NR
Without persistent sequelae			58	60 (19.0)	39 (67.2)	COPD 2 (3.4); diabetes 8 (13.8); cardiovascular disease 10 (17.2); hypertension 23 (39.7); cancer 1 (1.7); autoimmune diseases 1 (1.7); any comorbidity 38 (65.5); median CCI 2 (IQR 2.0)	All hospitalized; ICU 5 (8.6)	WHO Severity Score: 3, 53 (91.4); 4, 0 (0); 5, 1 (1.7); 6, 4 (6.9)	NR
Mannheim / Germany [44]	April 2021	6 months post diagnosis	61	46 (16.5)	25 (41.0)	Median BMI 25.4 (IQR 4.5)	Non-hospitalized 55 (90.2); hospitalized 6 (9.8); ICU 2 (3.3)	Asymptomatic 4 (6.6); median severity 3.0 (1.5)	1-5 symptoms, 40 (65.6); >5 symptoms, 17 (27.9)
New Jersey / USA [59]	August 2021	Median 171 days (IQR 22) post diagnosis	93	20-39: 50 (53.8); 40-59: 31 (33.3); ≥60: 12 (12.9)	27 (29.0)	Chronic respiratory disorder 10 (10.8); obesity 31 (33.3); diabetes 2 (2.2); cardio/cerebrovascular disease 3 (3.2); hypertension 20 (21.5); autoimmune disease/immunosuppressant use 5 (5.4); any chronic illness 51 (54.8)	Non-hospitalized 88 (94.6); hospitalized 5 (5.4); ICU 0 (0)	Severe 24 (25.8); mild to moderate 55 (59.1); asymptomatic 14 (15.1)	NR
Stanford / USA [45]	July 2022		---	---	---	---	---	---	---

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

With persistent sequelae		6 months post diagnosis	42	51 (50.0)	15 (35.7)	NR		NR	NIH Case Severity - asymptomatic 0 (0.0); mild 26 (61.9); moderate 6 (14.3); severe 4 (9.5); critical 6 (14.3)	NR			
Without persistent sequelae			63	43 (58.0)	32 (50.8)	NR		NR	NIH Case Severity - asymptomatic 2 (3.2); mild 45 (71.4); moderate 8 (12.7); severe 5 (7.9); critical 3 (4.8)	NR			
Saxony / Germany [63] Neuropsychiatric phenotype	September 2022	6 months (IQR 4) post infection	---	---	---	---	Median BMI 25.6 (IQR 7.9); mean comorbidities 1.65 (max 6.0)	---	Non-hospitalized 99 (94.3); hospitalized 4 (3.8); ICU 1 (1.0)	---	No symptoms or mild symptoms 99 (94.3)	---	NR
Without phenotype			55	56 (20.5)	27 (49.1)	Median BMI 27.6 (IQR 5.6)		NR		NR		NR	
Boston / USA [46]	September 2022	Up to 12 months post discharge	589	56 (14.4)	359 (61.0)	NR		All hospitalized		NR		NR	
Udine / Italy [47,48]	August 2022	Mean 13.5 months (SD 0.6) post infection	479	Mean 53 years; 18-40: 107 (22.3); 41-60: 205 (42.8); >60: 167 (34.9)	227 (47.4)	Chronic respiratory disease 17 (3.6); obesity 78 (16.3); diabetes 25 (5.3); hypertension 106 (22.6); CVD 7 (1.5); no comorbidities 230 (48.0); 1 comorbidity 135 (28.2); 2 comorbidities 66 (13.8); 3 comorbidities 31 (6.5); ≥4 comorbidities 17 (3.5)		Non-hospitalized 340 (71.0); hospitalized 139 (29.0); ICU 21 (4.4)	Asymptomatic 38 (8.0); mild 323 (67.7); moderate/severe/critical 116 (24.3)		0 - 66 (13.8); 1 - 66 (13.8); 2 - 97 (20.2); 3 - 74 (15.4); 4 - 76 (15.9); ≥5 - 100 (20.9)		

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

San Francisco / USA [49,50,64,66] With persistent sequelae	September 2022	Median 123 days (IQR 21) post infection	---	---	---	---	Lung problems 13 (17.8); BMI category, kg/m ² ≤24.9, 26 (35.6); 25 - 29.9, 18 (24.7); ≥30, 28 (38.4); autoimmune disease 8 (11.0); cancer 2 (2.7); diabetes 8 (11.0)	Non-hospitalized 54 (74.0); hospitalized 19 (26.0)	NR	NR
Without persistent sequelae			48	45 (21.5)	27 (56.3)		Lung problems - 10 (20.8); BMI category, kg/m ² ≤24.9, 20 (41.7); 25 - 29.9, 16 (33.3); ≥30, 11 (22.9); autoimmune disease 1 (2.1); cancer 1 (2.1); diabetes 6 (12.5)	Non-hospitalized 40 (83.3); hospitalized 8 (16.7)	NR	NR
Paris / France [51]	March 2022	3 and 7 months post first serology	74	47 (21.0)	13 (17.6)	BMI kg/m ² 23.7 (4.5)		All non-hospitalized	Asymptomatic 9 (12.2)	NR
Heidelberg / Germany [52]	April 2022	5, 9, and 12 months post onset	96	57 (13.0)	43 (44.8)	Asthma 12 (12.5); BMI >30 kg/m ² 23 (24.0); diabetes type 2 7 (7.3); hypertension 35 (35.1); CVD 4 (4.2); active malignancy 4 (4.2); autoimmune disease 5 (5.2)		Non-hospitalized 65 (67.7); hospitalized 31 (32.3)	Mild 15 (15.6); moderate 53 (55.2); severe 24 (25.0); critical 4 (4.2)	NR
Maryland / USA [53]* With persistent sequelae	May 2022	Median 149 days (IQR 105) post onset	---	---	---	---	Asthma 16 (15.4); diabetes 9 (8.7); hypertension 20 (19.2); CVD 2 (1.9); CAD 2 (1.9); valvular heart disease 1 (1.0); atrial fibrillation 0 (0); HIV infection 0 (0); median BMI 29.3 (IQR 10.4); obesity 46 (44.2)	Non-hospitalized 93 (89.4); hospitalized 11 (10.6)	Asymptomatic 0 (0.0)	NR

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

Without persistent sequelae			85	52 (28.0)	48 (56.5)	Asthma 8 (9.4); diabetes 2 (2.4); hypertension 19 (22.4); CVD 4 (4.7); CAD 1 (1.2); valvular heart disease 2 (2.4); atrial fibrillation 2 (2.4); HIV infection 4 (4.7); median BMI 28.6 (IQR 6.8); obesity 26 (30.6)	Non-hospitalized 74 (87.1); hospitalized 11 (12.9)	Asymptomatic 5 (5.9)	NR
Tyrol / Austria [54]	February 2022	Median 103 days (IQR 21); median 190 days (IQR 15) post diagnosis	145	57 (14.3)	82 (56.6)	Pulmonary disease 27 (18.6); obesity (BMI >30 kg/m2) 28 (19.3); CVD 58 (40.0); malignancy 17 (11.7); immunosuppression 6 (4.1); any comorbidities: 112 (77.2)	Non-hospitalized 36 (24.8); hospitalized 109 (75.2); ICU 32 (22.1)	Mild 36 (24.8); moderate 37 (25.5); severe 40 (27.6); critical 32 (22.1)	NR
Turkey / Istanbul [67] **	March 2022	6 months post diagnosis	248	35 (9.0)	94 (37.9)	No comorbidities	All non-hospitalized	NR	NR
Hungary / Pecs [30,65]	January 2022	---	---	---	---	---	---	---	---
Severe fatigue		Median 203 days (IQR 54) post onset	57	50 (12.0)	18 (31.6)	Mean BMI 26.7 (SD 5.0)	Non-hospitalized 42 (73.7); hospitalized 15 (26.3)	---	NR
Non-severe fatigue		Median 208 days (IQR 77) post onset	50	50 (12.0)	23 (46.0)	Mean BMI 27.7 (SD 7.0)	Non-hospitalized 25 (50.0); hospitalized 25 (50.0)	---	NR
Sweden / Region of Östergötland (RÖ) [62]	December 2021	Median 142 days (IQR 43) post discharge	158	57 (13.8)	97 (61.4)	Respiratory disease 33 (20.9); obesity 13 (8.2); diabetes 38 (24.1); CVD 31 (19.6); hypertension 64 (40.5); cancer 5 (3.2); 110 (69.6) any comorbidities	All hospitalized	Moderate 102 (64.6); severe 56 (35.4)	NR

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

Amsterdam / The Netherlands [55]	July 2022	---	---	---	---	---	---	---	---
With persistent sequelae	Median 376 days (IQR 286.0) post study inclusion	186	54 (23.0)	101 (54.3)	Median 26.8 (IQR 7.3); BMI category, normal - 68 (36.6); overweight - 62 (33.3); obese 51 (27.4); number of COVID-19 high-risk comorbidities: none - 93 (50.0); 1 - 46 (24.7); 2 - 27 (14.5); 3 or more - 20 (10.8)	Nonhospitalized 36 (19.4); hospitalized 117 (63.0); ICU 33 (17.7)	Mild 31 (16.7); moderate 90 (48.4); severe/critical 65 (35.0)	NR	
Without persistent sequelae	Median 363 days (IQR 195.0) post study inclusion	130	46 (25.0)	80 (61.5)	Median BMI 25.1 (IQR 4.8); BMI category, normal - 62 (47.7); overweight - 43 (33.1); obese 20 (15.4); number of COVID-19 high-risk comorbidities: none - 85 (65.4); 1 - 27 (20.8); 2 - 10 (7.7); 3 or more - 8 (6.2)	Nonhospitalized 85 (65.4); hospitalized 36 (27.7); ICU 9 (6.9)	Mild 61 (47.0); moderate 52 (40.0); severe/critical 17 (13.1)	NR	
Xiangyang / China [56]	October 2021	Median 348 days (IQR 7.0) post onset	121	49 (17.0)	50 (41.3)	Median BMI 23.9 (IQR 3.1); diabetes 8 (6.6); CVD 3 (2.5); hypertension 31 (25.6); autoimmune diseases 2 (1.7); cancer 1 (0.8); any comorbidity 37 (30.6)	All hospitalized; ICU 10 (8.3)	Non-severe 102 (84.3); severe 19 (15.7)	NR

Results are presented as N(%), unless otherwise specified

^aIn the event of multiple reports from the same study population, we presented characteristics from the most recent report. Number of study populations = 23;

^bWhere possible, characteristics reported for subgroups with/without persistent sequelae as assessed by study authors. If these data were not available, we reported characteristics for all participants with previous COVID-19 infection;

*Cross-sectional study; ** retrospective cohort study; *** case-control study

COMPASS - Composite Autonomic Symptom Score; BMI - body mass index; COPD - chronic obstructive pulmonary disease; CAD - coronary artery disease; ICU - intensive care unit; CCI - Charlson Comorbidity Index; WHO - World Health Organization; NIH - National Institutes of Health; SD - standard deviation; CVD - cardiovascular disease; IQR - interquartile range; NR - Not reported

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

Table 2: Quality assessment using the Newcastle-Ottawa Scale for cohort studies

Study	Selection				Comparability			Outcome	
	Representativeness of exposed cohort	Selection of unexposed cohort	Ascertainment of exposure	Outcome not present at start of study	Controlling for severity/LOC required during acute illness	Controlling for other predictors of PCC	Assessment of outcome	Length of follow-up	Adequacy of follow-up
Augustin (2021) [43]	*	*	*	NR	*	*	*	*	*
Bilich (2022) [42]	*	*	*	NR	NR	NR	NR	*	*
Blomberg (2021) [58]	*	NR	*	NR	*	*	NR	*	*
Cervia (2022) [29]	*	*	*	NR	*	*	NR	*	*
Garcia-Abellan (2021) [28]	NR	*	*	NR	*	*	NR	*	*
Garcia-Abellan (2022) [60]	NR	*	*	NR	*	*	NR	*	NR
Gerhards (2021) [44]	*	*	*	NR	NR	NR	NR	*	NR
Horton (2021) [59]	NR	*	NR	NR	NR	NR	NR	*	NR
Jia (2022) [45]	*	*	*	NR	NR	NR	*	*	NR
Lier (2022) [63]	NR	*	*	NR	NR	NR	NR	*	NR
Molnar (2021) [65]	*	*	*	*	*	*	NR	*	*
Ozonoff (2022) [46]	*	*	*	NR	NR	NR	NR	*	NR
Peghin (2021) [47]	*	*	*	*	*	*	*	*	*
Peghin (2022) [48]	NR	*	*	*	NR	*	NR	*	NR
Peluso (2021A) [49]	*	*	*	*	NR	NR	NR	*	NR
Peluso (2021B) [50]	*	*	*	*	*	*	NR	*	*
Peluso (2022) [64]	*	*	*	*	*	*	NR	*	NR
Pilmis (2022) [51]	NR	*	NR	NR	NR	NR	NR	*	NR
Seeble (2022) [52]	*	*	*	*	NR	*	NR	*	*
Sonnweber (2022) [54]	*	*	*	NR	NR	NR	NR	*	*
Stavileci (2022) [67]	*	*	*	*	*	*	*	*	NR
Varnai (2022) [30]	*	*	*	NR	*	*	NR	*	NR
Wahlgen (2022) [62]	NR	*	*	*	NR	NR	*	*	*
Wynberg (2022) [55]	*	*	*	*	NR	*	NR	*	NR
Zhan (2021) [56]	NR	*	*	NR	*	*	*	*	NR

*Study met criteria; NR - study did not meet criteria or was not reported
 LOC – level of care

SEROLOGICAL MARKERS AND POST-COVID-19 CONDITION

Table 3: Quality assessment using the Newcastle-Ottawa Scale for case-control studies

Study	Selection			Comparability			Exposure		
	Adequacy of case definition	Representativeness of cases	Selection of controls	Definition of controls	Controlling for severity/LOC required during acute illness	Controlling for other predictors of PCC	Ascertainment of exposure	Ascertainment of cases and controls	Non-response rate
Díaz-Salazar (2022) [57]	NR	*	*	*	*	NR	NR	*	*

*Study met criteria; NR - study did not meet criteria or was not reported

Table 4: Quality assessment using the Newcastle-Ottawa Scale for cross-sectional studies

Study	Selection			Comparability			Exposure	
	Representativeness of sample	Comparability between respondents and non-respondents	Ascertainment of exposure	Controlling for severity/LOC required during acute illness	Controlling for other predictors of PCC	Assessment of outcome	Statistical test	
Anaya (2021) [61]	*	*	*	NR	NR	NR	*	
Durstenfeld (2022) [66]	*	*	*	*	*	NR	*	
Sneller (2022) [53]	*	*	*	NR	*	NR	NR	

*Study met criteria; NR - study did not meet criteria or was not reported